Market Overview
The Asia-Pacific Antibody-Drug Conjugates (ADC) Market reached US$ XX million in 2023 and is expected to reach USnbsp; XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Antibody-drug conjugates (ADC) integrate the precision of monoclonal antibodies with the strength of cytotoxic drugs, enabling accurate targeting and treatment of tumors. This targeted delivery method improves therapeutic effectiveness and minimizes the systemic toxicity often linked to conventional chemotherapy. By attaching to particular antigens on cancer cells, ADCs promote the uptake of the cytotoxic agent, resulting in cell death while protecting healthy cells.
Antibody-drug conjugates (ADCs) signify a major innovation in cancer treatment by integrating targeted delivery mechanisms with powerful cytotoxic effects, thereby enhancing treatment efficacy while reducing adverse side effects. With a robust pipeline of emerging therapies and a growing number of approvals, ADCs are set to play a vital role in the future of oncology, providing promising options for improved management of various cancer types.
According to WHO, breast cancer is the most prevalent cancer among women and ranks as the second most common cancer. In 2022, approximately 2.3 million women were diagnosed with breast cancer, leading to around 670,000 deaths worldwide. These factors have driven the Asia-Pacific antibody-drug conjugates (ADC) market expansion.
Executive Summary
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing cancer incidence
The rising incidence of cancer is a significant driver for the Asia-Pacific antibody-drug conjugates (ADC) market. As the number of cancer cases continues to grow, there is a growing need for more effective and targeted therapies, which ADCs can provide. This targeted therapy approach allows for greater efficacy and reduced toxicity compared to traditional chemotherapy, making ADCs an attractive option for both patients and healthcare providers.
In addition, advancements in antibody engineering and conjugation technologies are a major factor in improving the market opportunity of antibody-drug conjugates. Significant progress has been made in antibody engineering and conjugation technologies, enabling the development of more potent and stable ADCs.All these factors demand the Asia-Pacific antibody-drug conjugates (ADC) market.
Moreover, the rising demand for low-toxicity and effective drugs contributes to the Asia-Pacific antibody-drug conjugates (ADC) market expansion.
Heterogeneity in antibody-drug conjugates (ADCs)
One of the primary challenges in the development of antibody-drug conjugates (ADCs) is the heterogeneity that arises from the conjugation processes used to attach cytotoxic drugs to antibodies are expected to hinder the Asia-Pacific antibody-drug conjugates (ADC) market growth. The Drug-to-Antibody Ratio (DAR) indicates the number of cytotoxic drug molecules linked to each antibody molecule in an antibody-drug conjugate (ADC).
ADCs can be created using various conjugation techniques, including random conjugation to surface-exposed lysine residues or site-specific conjugation to engineered cysteines. Random conjugation often results in a mixture of products with varying attachment sites and DARs, complicating dosing regimens and potentially leading to less effective treatment outcomes. Thus, the above factors could be limiting the Asia-Pacific antibody-drug conjugates (ADC)market's potential growth.
Market Segment Analysis
The Asia-Pacific antibody-drug conjugates (ADC) market is segmented based on product type, target type, technology type, application, and end-user.
Application:
Breast cancer segment is expected to dominate the Asia-Pacific antibody-drug conjugates (ADC) market share
The breast cancer segment holds a major portion of the Asia-Pacific antibody-drug conjugates (ADC) market share and is expected to continue to hold a significant portion of the Asia-Pacific antibody-drug conjugates (ADC) market share during the forecast period.
Breast cancer is mostly seen in middle-aged and older women, with a median age of 62. Half of those diagnosed are 62 or younger, and a small number are younger than 45. Women with certain gene mutations, such as BRCA1 or BRCA2, have an increased risk of breast cancer.
Triple-negative breast Cancer (TNBC), which lacks HER2 and hormone receptor (estrogen and progesterone) expression, is being treated with ADCs. An ADC that has been approved for the treatment of metastatic TNBC is sacituzumab govitecan-hziy (Trodelvy). It targets Trop-2, a protein that is expressed on the cell surface of many solid cancers, including TNBC.
ADCs may enhance therapeutic results and lessen adverse effects. They can increase the therapeutic window and reduce harm to healthy tissues by targeting cancer cells with a powerful cytotoxic payload. To produce synergistic effects and maybe improve therapeutic outcomes, ADCs can also be coupled with other medicines, such as immune checkpoint inhibitors or other targeted therapies. These factors have solidified the segment's position in the Asia-Pacific antibody-drug conjugates (ADC) market.
Blood cancer segment is the fastest-growing segment in the Asia-Pacific antibody-drug conjugates (ADC) market share
The blood cancer segment is the fastest-growing segment in the Asia-Pacific antibody-drug conjugates (ADC) market share and is expected to hold the market share over the forecast period.
The rising prevalence of blood cancers, such as leukemia and lymphoma, in the Asia-Pacific region is creating a significant demand for effective treatment options. As traditional therapies often fail to deliver adequate responses, there is an urgent need for innovative treatments like antibody-drug conjugates (ADCs) that can specifically target these malignancies.
Recent developments in ADC technology have markedly enhanced their efficacy and safety profiles, particularly for blood cancers. Innovations in linker chemistry and the formulation of more potent cytotoxic agents have improved the ability of ADCs to deliver therapeutic payloads directly to cancer cells while minimizing harm to healthy tissues. These advancements position ADCs as a preferred treatment option for hematological malignancies.
For instance, in February 2024, Daiichi Sankyo officially launched its subsidiary in Singapore as part of its strategic expansion to enhance the reach of its antibody-drug conjugates (ADCs) for cancer treatment. This initiative reflects the company's commitment to addressing unmet medical needs in oncology, particularly in a region where cancer accounts for nearly 30% of all deaths. These factors have solidified the segment's position in the Asia-Pacific antibody-drug conjugates (ADC) market.
Product Type :
Kadcyla segment is expected to dominate the Asia-Pacific antibody-drug conjugates (ADC) market share
The kadcyla segment holds a major portion of the Asia-Pacific antibody-drug conjugates (ADC) market share and is expected to continue to hold a significant portion of the Asia-Pacific antibody-drug conjugates (ADC) market share during the forecast period.
The increasing incidence of breast cancer in the Asia-Pacific region is driving the demand for effective treatment options. This surge in cases necessitates reliable therapies like Kadcyla (ado-trastuzumab emtansine), which has demonstrated significant efficacy in clinical settings. As more patients are diagnosed with HER2-positive breast cancer, the need for effective antibody-drug conjugates (ADCs) will likely rise, further enhancing Kadcyla's market share.
Kadcyla is particularly effective in treating HER2-positive breast cancer, a prevalent and aggressive form of the disease. Its mechanism allows it to deliver a potent cytotoxic agent directly to cancer cells while minimizing damage to healthy tissues. This targeted delivery not only improves treatment outcomes but also reduces side effects compared to traditional chemotherapy, making Kadcyla a preferred choice among oncologists.
According to a ScienceDirect research publication in June 2024, antibody-drug conjugates (ADCs) such as Enhertu (DS-8201a) and Kadcyla (trastuzumab emtansine) have emerged as significant advancements in the treatment of HER2-positive breast cancer. These drugs are designed to deliver targeted therapy directly to cancer cells, improving treatment efficacy while minimizing damage to healthy tissues. These factors have solidified the segment's position in the Asia-Pacific antibody-drug conjugates (ADC) market.
Enhertu segment is the fastest-growing segment in the Asia-Pacific antibody-drug conjugates (ADC) market share
The enhertu segment is the fastest-growing segment in the Asia-Pacific antibody-drug conjugates (ADC) market share and is expected to hold the market share over the forecast period.
Enhertu has recently gained approval for treating HER2-low breast cancer, which includes tumors that have lower levels of the HER2 protein than traditionally targeted cancers. This is an advanced achievement because it opens treatment options for approximately half of all patients with metastatic breast cancer who previously had limited therapeutic options.
By effectively targeting both HER2-positive and HER2-low cancers, Enhertu positions itself as a versatile treatment option, increasing its adoption among oncologists. These factors have solidified the segment's position in the Asia-Pacific antibody-drug conjugates (ADC) market.
Market Geographical Share
Japan is expected to hold a significant position in the Asia-Pacific antibody-drug conjugates (ADC) market share
Japan holds a substantial position in the Asia-Pacific antibody-drug conjugates (ADC) market and is expected to hold most of the market share.
The antibody-drug conjugates (ADC) market in Japan is driven by several factors including the rising incidence of cancer, advancements in technology, supportive regulatory environments, a strong pipeline of research and development, and strategic partnerships that would drive this market growth.
Moreover, key player strategies such as partnerships and collaborations would drive this market growth in this country. For instance, In October 2024, Ono Pharmaceutical Co., Ltd. announced a significant partnership with LigaChem Biosciences, Inc. (LCB) to advance the development of LCB97, a preclinical antibody-drug conjugate (ADC) targeting solid tumors. Under this agreement, Ono secures exclusive worldwide rights to develop, manufacture, and commercialize LCB97, which is designed to be a first-in-class treatment for solid tumors.
Thus, the above factors are consolidating the country's position as a dominant force in the Asia-Pacific antibody-drug conjugates (ADC) market.
India is growing at the fastest pace in the Asia-Pacific antibody-drug conjugates (ADC) market.
India holds the fastest pace in the Asia-Pacific antibody-drug conjugates (ADC) market and is expected to hold most of the market share.
The Asia-Pacific antibody drug conjugates market in India is driven by factors such as the increasing prevalence of cancer, growing investments in research and developments related to cancer, increasing innovative and targeted treatment options, and advancements in antibody engineering and conjugation technologies.
India holds a major portion of the market share owing to the rising prevalence of cancer in India is a significant driver for ADCs, as these therapies offer targeted treatment options that can be more effective and less toxic than traditional chemotherapies.
For instance, In January 2023, Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has launched Palbociclib, a novel anti-cancer drug, in India for patients who have advanced breast cancer, the drug is available under the brand name PALENO. Thus, the above factors are consolidating the country's position as the fastest-growing force in the Asia-Pacific antibody-drug conjugates (ADC) market.
Market Competitive Landscape
The major Asia-pacific players in the Asia-Pacific antibody-drug conjugates (ADC) market include Pfizer, Inc., AstraZeneca, GSK plc, DAIICHI SANKYO COMPANY, LIMITED., F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., ADC Therapeutics, Astellas Pharma Inc., ImmunoGen, Inc., ACRO Biosystems., and RemeGen Co., Ltd. among others.
Emerging Players
The emerging players in the Asia-Pacific antibody-drug conjugates (ADC) market include Byondis, Araris Biotech, BioNTech, and Genmab A/S among others.
Metrics | Details | |
CAGR | XX% | |
Market Size Available for Years | 2022-2031 | |
Estimation Forecast Period | 2024-2031 | |
Revenue Units | Value (US$ Mn) | |
Segments Covered | Product Type | Adcetris, Perjeta, Kadcyla, Enhertu, Padcev, Trodelvy Polivy, Others |
Target Type | CD30 Antibodies, HER2 Antibodies, CD22 Antibodies, Others | |
Technology Type | Linker Technology, Payload Technology, Others | |
Application | Breast Cancer, Blood Cancer, Skin Cancer, Lung Cancer, Ovary Cancer, Others | |
End-User | Hospitals, Cancer Centers, Others | |
Countries Covered | India, Japan, South Korea, Australia, Indonesia, Malaysia, Singapore, Thailand, Rest of Asia-Pacific | |
Key Developments
- In October 2023, Daiichi Sankyo and Merck entered into a significant development and commercialization agreement for three of Daiichi Sankyo's DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The agreement allows Daiichi Sankyo and Merck to jointly develop and potentially commercialize the three ADC candidates on a scale, except in Japan, where Daiichi Sankyo retains exclusive rights.
- In August 2023, ImmunoGen, Inc. announced a significant collaboration with Takeda Pharmaceutical Company to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. By using this agreement, ImmunoGen grants Takeda exclusive rights to develop and market ELAHERE in Japan.
Why Purchase the Report?
- To visualize the Asia-Pacific antibody-drug conjugates (ADC) market segmentation based on product type, target type, technology type, application, and end-user, and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the antibody-drug conjugates (ADC) Market with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The Asia-Pacific antibody-drug conjugates (ADC) market report would provide approximately 51 tables, 47 figures, and 183 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
